SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-026990
Filing Date
2023-08-03
Accepted
2023-08-03 07:03:50
Documents
69
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q avtx-20230630.htm   iXBRL 10-Q 989394
2 EX-31.1 ex-3112q2023.htm EX-31.1 10537
3 EX-31.2 ex-3122q2023.htm EX-31.2 10323
4 EX-32.1 ex-3212q2023.htm EX-32.1 11086
10 GRAPHIC avtx-20230630_g1.jpg GRAPHIC 658726
  Complete submission text file 0001628280-23-026990.txt   7809469

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20230630.xsd EX-101.SCH 57394
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT avtx-20230630_cal.xml EX-101.CAL 64687
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avtx-20230630_def.xml EX-101.DEF 316474
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20230630_lab.xml EX-101.LAB 675811
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20230630_pre.xml EX-101.PRE 441168
63 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20230630_htm.xml XML 719784
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37590 | Film No.: 231138006
SIC: 2834 Pharmaceutical Preparations